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Abstract
Weight loss in metabolically healthy obese (MHO) subjects may result in deterioration of cardio-metabolic risk profile. We
analyzed the effects of weight loss induced by laparoscopic adjustable gastric banding (LAGB) on cardio-metabolic risk
factors in MHO and insulin resistant obese (IRO) individuals. This study included 190 morbidly obese non-diabetic subjects.
Obese individuals were stratified on the basis of their insulin sensitivity index (ISI), estimated from an OGTT, into MHO (ISI
index in the upper quartile) and IRO (ISI in the three lower quartiles). Anthropometric and cardio-metabolic variables were
measured at baseline and 6-months after LAGB. Six months after LAGB, anthropometric measures were significantly reduced
in both MHO and IRO. Percent changes in body weight, BMI, and waist circumference did not differ between the two
groups. Fasting glucose and insulin levels, triglycerides, AST, and ALT were significantly reduced, and HDL cholesterol
significantly increased, in both MHO and IRO subjects with no differences in percent changes from baseline. Insulin
sensitivity increased in both MHO and IRO group. Insulin secretion was significantly reduced in the IRO group only.
However, the disposition index significantly increased in both MHO and IRO individuals with no differences in percent
changes from baseline between the two groups. The change in insulin sensitivity correlated with the change in BMI
(r =20.43; P,0.0001). In conclusion, our findings reinforce the recommendation that weight loss in response to LAGB
intervention should be considered an appropriate treatment option for morbidly obese individuals regardless of their
metabolic status, i.e. MHO vs. IRO subjects.
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Introduction
Increasing evidence suggests that a subset of relatively insulin
sensitive obese subjects, referred to as metabolically healthy obese
(MHO) individuals, has a favorable cardio-metabolic risk profile
and a lower risk for type 2 diabetes and cardio-vascular disease, as
compared with insulin resistant obese (IRO) subjects [1,2]. It is
worth noting that the MHO phenotype is observed in a given
moment of the natural history of obesity, but it is unknown
whether MHO individuals will maintain their metabolic status or
develop over time the IRO phenotype. Whether the MHO
phenotype is associated with a lower risk for all-cause mortality is
an object of debate with divergent results reported by two recent
studies [3,4]. Mechanistically, several features might contribute to
the favorable cardio-metabolic profile of MHO individuals
including lower visceral adipose tissue accumulation, lower ectopic
fat accumulation in skeletal muscle and liver, lower blood pressure,
lower levels of triglycerides, free fatty acids, liver enzymes (as a
surrogate markers of fatty liver), inflammatory markers, higher
beta-cell function, higher estimated glomerular filtration rate, and
higher levels of HDL cholesterol, insulin-like growth factor 1
(IGF-1), and adiponectin [5–11].
A controversial question is whether MHO individuals would
have any cardio-metabolic benefit from weight loss. Studies
assessing the effects of lifestyle interventions, including diet and/or
exercise, in MHO individuals have led to divergent results [12–
15]. Three studies have reported an improvement in the cardio-
metabolic risk profile in IRO, but not in MHO, subjects, despite
similar weight loss [12–14], whereas one study has shown an
improvement in cardio-metabolic risk factors of MHO individuals
after a weight loss intervention [15]. Laparoscopic adjustable
gastric banding (LAGB) has been proposed as a therapeutic
approach to achieve durable weight loss in morbidly obese subjects
[16]. Because bariatric surgery-induced weight loss is associated
with an improvement of the cardio-metabolic risk profile in
morbidly obese subjects [16,17], we sought to investigate the
effects of LAGB-induced weight loss on cardio-metabolic risk
factors among MHO and IRO individuals.
Materials and Methods
Subjects
The study group consisted of 190 morbidly obese non-diabetic
subjects consecutively recruited at the Istituto Clinico Sant’Am-
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brogio, Ospedale San Paolo and Ospedale San Raffaele, Milano,
Italy. All subjects were Caucasian. Eligibility criteria, time-schedules
for assessments, and diet after LAGB have been described
previously in detail [16–18]. All anthropometric and biochemical
measurements were made in the morning after a 12-h fast using
standardized methods. Height and weight were measured to the
nearest 0.5 cm and 0.1 kg, respectively. Waist (at the midpoint
between the lateral iliac crest and lowest rib) was measured to the
nearest 0.5 cm. A 75 g oral glucose tolerance test (OGTT) was
performed with sampling for plasma glucose and insulin. After
LAGB, subjects were reevaluated by a dietitian and a physician at
fortnight intervals for 2 months and then monthly up to 6 months, as
previously described [16–18]. The study was approved by the
Istituto San Raffaele Ethics Committee and by the Review Board of
the University "Magna Graecia" of Catanzaro, and informed
written consent was obtained from each participant.
Analytical determinations
Plasma glucose was measured by the glucose oxidation method
(YSI, Inc., Yellow Springs, OH). Triglyceride levels were assayed
by an enzymatic technique on a Cobas Fara II Centrifugal
Analyser (Cobas Fara II; Roche, Basel, Switzerland). Total
cholesterol and HDL-cholesterol levels were assayed by enzymatic
automated spectrophotometric methods with a Cobas Fara II.
Insulin was assayed by a Microparticle Enzyme Immunoassay
(IMX; Abbott Laboratories, Abbott Park, IL) with a monoclonal
antibody without cross-reactivity with human proinsulin. Alanine
aminotransferase (ALT) and aspartate aminotransferase (AST)
were determined by standard laboratory methods.
Calculations
A previously validated index (ISI) derived from the OGTT [19]
was used to estimate insulin sensitivity. Men and women
separately were stratified into quartiles according to their insulin
sensitivity estimated from the OGTT results. Men and women in
the upper quartile were then combined and were defined as
MHO, while men and women in the three other quartiles were
defined as being insulin resistant obese (IRO). Glucose-stimulated
insulin secretion was estimated by the Stumvoll index for first
phase insulin secretion as previously described [20]. To evaluate b-
cell function, the so called disposition index was calculated as the
product of the ISI and the Stumvoll index for first phase insulin
secretion. Change in variables at the 6-month follow-up were
calculated as follows: ([Variable6-month follow-up2 Variablebaseline] /
Variablebaseline)6 100.
Statistical analysis
Triglycerides, ALT, AST, fasting insulin and insulin values
during OGTT were natural log transformed for statistical analysis
due to their skewed distribution. Continuous data are expressed as
means 6 SD. Categorical variables were compared by x2 test. In
the within-group test, differences between baseline and follow-up
variables were tested by paired t-test. In the between-groups test,
differences in variables between the two groups (MHO vs. IRO
group) were analyzed using Student’s t-test. Relationships between
changes of variables were determined by Pearson’s correlation
coefficient (r). A P value ,0.05 was considered statistically signi-
ficant. All analyses were performed using the SPSS software
programme Version 16.0 for Windows.
Table 1. Clinical characteristics and laboratory data at baseline and after LAGB intervention in MHO and IRO subjects.
Variables
MHO
Baseline
MHO 6-months
follow-up 1P
IRO
Baseline
IRO 6-months
follow-up 1P
Male/Female 8/40 --- 40/119 ---
Age (years) 38610 --- 40610 ---
Body weight (kg) 108616 92614 ,0.0001 118620** 102617*** ,0.0001
BMI (kg/m2) 41.165.5 35.065.3 ,0.0001 44.066.4** 38.265.6** ,0.0001
Waist circumference (cm) 115612 100610 ,0.0001 123613** 109612*** ,0.0001
Fasting Glucose (mgl/dl) 93612 88612 0.009 102614*** 95612** ,0.0001
2 h glucose (mgl/dl) 105620 101630 0.32 130639*** 118637** 0.001
Fasting Insulin (mU/ml) 1163 863 0.001 20612*** 1266*** ,0.0001
2-h insulin (mU/ml) 27617 31623 0.32 78657*** 57646*** ,0.0001
Total cholesterol (mg/dl) 202641 203645 0.88 203638 202635 0.59
HDL (mg/dl) 48612 52612 0.02 49612 51613 0.002
Triglycerides (mg/dl) 119653 100646 ,0.0001 140669 115649 ,0.0001
ALT (UI/l) 28614 22614 0.009 36625* 24614 ,0.0001
AST (UI/l) 2267 1967 0.005 26615 1968 ,0.0001
ISI 108631 141651 0.02 47618*** 84646*** ,0.0001
Stumvoll first-phase index 11406332 11426395 0.96 17406845*** 14126684* ,0.0001
Disposition index 121708640793 153107660566 0.01 73870630773*** 105675654677** ,0.0001
Data are means6 SD. Triglycerides, ALT, AST, fasting, and 2-h insulin were log transformed for statistical analysis, but values in the table represent a back transformation
to the original scale. Categorical variables were compared by x2 test. 1P values for differences between baseline and follow-up variables tested by paired t-test. *P
values for differences of continuous variables between the two groups using unpaired Student’s t.
*P ,0.01 vs. MHO,
**P ,0.001 vs. MHO;
***P ,0.0001 vs. MHO.
doi:10.1371/journal.pone.0017737.t001
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Results
Baseline study
The clinical characteristics and laboratory data for MHO and
IRO subjects at baseline are shown in Table 1. By design, insulin
sensitivity, measured by ISI, was higher in MHO subjects (108631)
as compared with IRO individuals (47618; P,0.0001). The ISI
value of MHO subjects was similar to the mean value obtained for
332 non-obese individuals (128 men and 204 women; age= 42614,
BMI=23.862.2, ISI= 114654) participating to the to the
CAtanzaro MEtabolic RIsk factors (CATAMERI) Study, a cross-
sectional study assessing cardio-metabolic risk factors in an
ambulatory care setting [21,22]. No statistically significant differ-
ences in gender, age, total cholesterol, triglycerides, HDL
cholesterol, and AST were observed between the two groups of
obese individuals. IRO subjects showed significantly higher body
weight, BMI, waist circumference, fasting and 2-h glucose levels,
fasting and 2-h insulin levels, ALT, and insulin secretion index as
compared with MHO subjects. Since insulin secretion is dependent
on the actual insulin sensitivity, we compared the disposition index,
an integrated measure of the ability of the b-cells to compensate for
insulin resistance, between the two groups. IRO individuals
exhibited a lower disposition index as compared with MHO
subjects, suggesting that the IRO phenotype is associated with a
decreased ability to compensate for insulin resistance.
Follow-up study after LAGB
Six months after LAGB intervention, body weight, BMI, and
waist circumference were significantly reduced in both MHO and
IRO subjects. Percent changes in body weight, BMI (Figure 1),
and waist circumference did not differ between MHO and IRO
group (Table 2). Fasting glucose and insulin levels, triglycerides,
AST, and ALT significantly reduced and HDL cholesterol
significantly increased in both MHO and IRO subjects with no
difference in percent changes from baseline between the two
groups (Table 2). 2-h glucose and insulin levels were significantly
reduced in the IRO group only. Insulin sensitivity, assessed by ISI,
increased in both MHO and IRO group (Table 2); the percent
change was significantly greater in the IRO group (Figure 1).
Insulin secretion was significantly reduced in the IRO group, while
no change was observed in the MHO group. However, the
disposition index significantly increased in both MHO and IRO
individuals with no significant difference in percent changes from
baseline between the two groups. In both groups, the change in
insulin sensitivity correlated with the change in BMI ( r = 20.43;
P,0.0001) (Figure 2). This correlation was stronger in the IRO
group (r = 20.49; P,0.0001) than in the MHO group (r =
20.39; P=0.005).
Discussion
Obesity has constantly been associated with cardio-metabolic
abnormalities, including dysglycemia, insulin resistance, hyperten-
sion, dyslipidemia, which may increase the risk of cardiovascular
diseases and type 2 diabetes. However, increasing evidence
suggests that obesity is a heterogeneous disorder with a subset of
obese subjects, known as metabolically healthy obese (MHO), that
appears to be protected against obesity-related cardio-metabolic
abnormalities [1–11]. Lifestyle intervention is considered the
primary treatment strategy for all obese individuals; however,
bariatric surgery has been successfully employed to achieve stable
reduction of body weight in morbidly obese individuals [16,17].
Recent studies have raised the question of whether MHO subjects
may gain any additional cardio-metabolic benefit from weight loss;
three studies have reported no change in cardio-metabolic risk
profile or a paradoxical deterioration in insulin sensitivity in MHO
subjects despite significant weight loss [12–14], whereas one study
has shown an improvement in cardio-metabolic risk factors among
MHO individuals after lifestyle intervention [15]. Our results are
in agreement with the latter study as we observed that, six months
after LAGB intervention, MHO individuals had a significant
improvement in cardio-metabolic risk factors including an increase
of insulin sensitivity, b-cell function, and HDL cholesterol, and a
reductions of fasting glucose and insulin levels, triglycerides, and
liver enzymes (surrogate markers of fatty liver). Importantly, to the
best of our knowledge, this is the first study assessing the effects of
LAGB intervention on MHO individuals. Several explanations
may account for the differing results of the present study as
compared with previous studies. The most obvious explanation is
related to the greater reduction of body weight obtained after
LAGB intervention as compared with lifestyle intervention. After a
6-months lifestyle intervention, weight loss in MHO individuals
ranged from 25 kg to 22.4 kg [12–15], whereas, after LAGB
intervention, body weight decreased by 16 kg in MHO individ-
uals. Given that the reduction in BMI was strongly correlated with
the increase in insulin sensitivity (Figure 1), it seems plausible that
a critical amount of total adiposity must be lost before observing a
beneficial effect of weight loss on insulin sensitivity. Other
potential mechanisms explaining the present results include
changes in ghrelin or incretins release.
Strengths of the present study include the relatively large sample
size, the longitudinal design, the inclusion of both sexes, the well
Figure 1. Change (%) in BMI and insulin sensitivity assessed as
ISI at 6-month follow-up after laparoscopic adjustable gastric
banding (LAGB) intervention in MHO and IRO subjects.
doi:10.1371/journal.pone.0017737.g001
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Table 2. Change (%) in clinical characteristics and laboratory data at 6-month follow-up after LAGB intervention in MHO and IRO
subjects.
Variables
MHO Change (%) at 6-month
follow-up
IRO Change (%) at 6-month
follow-up P for % change between the two
Body weight (kg) 21464 21366 0.10
BMI (kg/m2) 21464 21366 0.10
Waist circumference (cm) 21266 21065 0.08
Fasting Glucose (mgl/dl) 26.762.5 28.961.6 0.60
2 h glucose (mgl/dl) 21.464.9 24.062.8 0.65
Fasting Insulin (mU/ml) 23869 291611 0.006
2-h insulin (mU/ml) 232617 2105615 0.008
Total cholesterol (mg/dl) 21.061.8 21.361.1 0.91
HDL (mg/dl) 5.463.0 3.761.7 0.62
Triglycerides (mg/dl) 22465 22566 0.85
ALT (UI/l) 24269 25968 0.11
AST (UI/l) 21664 23065 0.03
ISI 31629 97680 ,0.0001
Stumvoll first-phase index 565 2865 0.11
Disposition index 865 18615 0.20
Data are means 6 SD. Triglycerides, ALT, AST, fasting, and 2-h insulin were log transformed for statistical analysis, but values in the table represent a back
transformation to the original scale. Categorical variables were compared by x2 test. 1P values for differences between baseline and follow-up variables tested by paired
t-test. *P values for differences of continuous variables between the two groups using unpaired Student’s t. *P ,0.01 vs. MHO, **P ,0.001 vs. MHO; ***P ,0.0001 vs.
MHO.
doi:10.1371/journal.pone.0017737.t002
Figure 2. Correlation between percent changes in BMI and ISI after laparoscopic adjustable gastric banding (LAGB) intervention.
doi:10.1371/journal.pone.0017737.g002
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characterized cohort of morbidly obese individuals with simulta-
neous assessment of plasma glucose and insulin levels during an
OGTT and cardio-metabolic risk factors, and the centralization of
laboratory analyses. Nonetheless, the present study has some
limitations. Most notably, all biochemical variables, including
plasma glucose during OGTT were measured once, a common
limitation to most epidemiological studies. In addition, the present
findings are only based on Caucasian individuals, and results
might vary as a function of ethnic group. Finally, we have not
assessed cardiovascular function indexes, such as endothelial-
mediated vasodilatation or arterial stiffness, that may be modified
by weight loss.
As restricted health care resources lead to the need to prioritize
high-risk obese individuals for aggressive treatment, including
bariatric surgery, the notion that subjects with uncomplicated
obesity would not benefit from weight loss seems a misguided
message to both regulatory authorities and public opinion. Our
findings reinforce the recommendation that weight loss in response
to bariatric surgery intervention should be considered an
appropriate treatment option for all morbidly obese individuals,
regardless of their metabolic status, i.e. MHO vs. IRO subjects.
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